Skip to content

A Post-Intervention Surveillance Study Regarding the Acquisition Rate of ESBL-KP, Ecoli

Association of Antibiotic Utilization Measures and Control of Extended-Spectrum β-Lactamases (ESBLs) (A Post-Intervention Surveillance Study)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00724919
Enrollment
256
Registered
2008-07-30
Start date
2003-12-31
Completion date
2004-04-30
Last updated
2008-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection

Keywords

ESBL

Brief summary

To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, post- intervention in the selected medical centres

Detailed description

This is post-interventional study to follow the acquisition rate of ESBP producing E. coli or K. pneumoniae at the sites involved in a previous interventional study.

Interventions

None listed

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Inclusion 1. All patients admitted or transferred to ICU/burn unit. 2. Patients of either sex, 18 years of age or older. Exclusion Patients were excluded if they had underlying conditions or diseases that were ultimately fatal within 48 hours

Design outcomes

Primary

MeasureTime frame
The acquisition rate of ESBL producing E. coli or K. pneumoniae at the end of surveillance phase48hours

Secondary

MeasureTime frame
The infection rate due to ESBL producing E. coli, or due to K. pneumoniae at the end of surveillance phase48hours

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026